Statin Use Before and After the KDIGO Lipids in Chronic Kidney Disease Guideline: A Population-based Interrupted Time Series Analysis

Overview

Journal Basic Clin Pharmacol Toxicol

Specialties Pharmacology
Toxicology

Date 2022 Jun 28

PMID 35762022

Authors

Jan D Kampmann

Mads Nybo

Frans Brandt

Henrik Stovring

Per Damkier

Daniel P Henriksen

Lars C Lund

Affiliations

Soon will be listed here.

Abstract

In November 2013, the Kidney Disease: Improving Global Outcomes Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease was published, recommending statins for all individuals 50 years or older with an estimated glomerular filtration rate below 60 ml/min/1.73 m to lower the risk of major cardiovascular events. We quantified the prevalence of statin use among the target population before and after the guideline publication in a large Danish cohort of individuals with an estimated glomerular filtration rate below 60 ml/min/1.73 m , to investigate the effect of the guideline, but found no difference in the prevalence of statin use prior to and after the guideline publication.

Citing Articles

Rate and Risk Factors of Acute Myocardial Infarction after Debut of Chronic Kidney Disease-Results from the KidDiCo.

Kampmann J, Heaf J, Mogensen C, Petersen S, Wolff D, Mickley H J Cardiovasc Dev Dis. 2022; 9(11).

PMID: 36354786 PMC: 9696870. DOI: 10.3390/jcdd9110387.

Statin use before and after the KDIGO Lipids in chronic kidney disease guideline: A population-based interrupted time series analysis.

Kampmann J, Nybo M, Brandt F, Stovring H, Damkier P, Henriksen D Basic Clin Pharmacol Toxicol. 2022; 131(5):306-310.

PMID: 35762022 PMC: 9795967. DOI: 10.1111/bcpt.13768.

References

Fellstrom B, Jardine A, Schmieder R, Holdaas H, Bannister K, Beutler J . Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009; 360(14):1395-407. DOI: 10.1056/NEJMoa0810177. View

Frank L . Epidemiology. The epidemiologist's dream: Denmark. Science. 2003; 301(5630):163. DOI: 10.1126/science.301.5630.163. View

Chung Y, Lee Y, Chang C, Lin M, Lin J, Lai M . Statins of high versus low cholesterol-lowering efficacy and the development of severe renal failure. Pharmacoepidemiol Drug Saf. 2013; 22(6):583-92. DOI: 10.1002/pds.3433. View

Wiggins B, Saseen J, Page 2nd R, Reed B, Sneed K, Kostis J . Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2016; 134(21):e468-e495. DOI: 10.1161/CIR.0000000000000456. View

Matsushita K, Sang Y, Ballew S, Astor B, Hoogeveen R, Solomon S . Cardiac and kidney markers for cardiovascular prediction in individuals with chronic kidney disease: the Atherosclerosis Risk in Communities study. Arterioscler Thromb Vasc Biol. 2014; 34(8):1770-7. PMC: 4172337. DOI: 10.1161/ATVBAHA.114.303465. View

Wagner A, Soumerai S, Zhang F, Ross-Degnan D . Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002; 27(4):299-309. DOI: 10.1046/j.1365-2710.2002.00430.x. View

Henriksen D, Damkier P, Hallas J, Nybo M . Sixteen years of creatinine measurements among 460 000 individuals-The Funen Laboratory Cohort (FLaC), a population-based pharmacoepidemiological resource to study drug-induced kidney disease. Basic Clin Pharmacol Toxicol. 2018; 124(5):582-590. DOI: 10.1111/bcpt.13167. View

Schmidt I, Hubner S, Nadal J, Titze S, Schmid M, Barthlein B . Patterns of medication use and the burden of polypharmacy in patients with chronic kidney disease: the German Chronic Kidney Disease study. Clin Kidney J. 2019; 12(5):663-672. PMC: 6768303. DOI: 10.1093/ckj/sfz046. View

Tonelli M, Wanner C . Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline. Ann Intern Med. 2013; 160(3):182. DOI: 10.7326/M13-2453. View

10.

Gasparini A, Evans M, Coresh J, Grams M, Norin O, Qureshi A . Prevalence and recognition of chronic kidney disease in Stockholm healthcare. Nephrol Dial Transplant. 2016; 31(12):2086-2094. PMC: 5146708. DOI: 10.1093/ndt/gfw354. View

11.

Galan I, Verdalles U, Garcia de Vinuesa M, Quiroga B, Goicoechea M, Perez A . Impact of the application of the JNC 8 and KDIGO-2013 guidelines on hypertension and lipid control in a Nephrology outpatient clinic. Nefrologia (Engl Ed). 2018; 38(4):379-385. DOI: 10.1016/j.nefro.2017.10.003. View

12.

Mollazadeh H, Tavana E, Fanni G, Bo S, Banach M, Pirro M . Effects of statins on mitochondrial pathways. J Cachexia Sarcopenia Muscle. 2021; 12(2):237-251. PMC: 8061391. DOI: 10.1002/jcsm.12654. View

13.

Baigent C, Landray M, Reith C, Emberson J, Wheeler D, Tomson C . The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011; 377(9784):2181-92. PMC: 3145073. DOI: 10.1016/S0140-6736(11)60739-3. View

14.

Schneider M, Hubner S, Titze S, Schmid M, Nadal J, Schlieper G . Implementation of the KDIGO guideline on lipid management requires a substantial increase in statin prescription rates. Kidney Int. 2015; 88(6):1411-1418. DOI: 10.1038/ki.2015.246. View

15.

Bangalore S, Fayyad R, Hovingh G, Laskey R, Vogt L, DeMicco D . Statin and the risk of renal-related serious adverse events: Analysis from the IDEAL, TNT, CARDS, ASPEN, SPARCL, and other placebo-controlled trials. Am J Cardiol. 2014; 113(12):2018-20. DOI: 10.1016/j.amjcard.2014.03.046. View

16.

Serban M, Colantonio L, Manthripragada A, Monda K, Bittner V, Banach M . Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction. J Am Coll Cardiol. 2017; 69(11):1386-1395. DOI: 10.1016/j.jacc.2016.12.036. View

17.

Kampmann J, Nybo M, Brandt F, Stovring H, Damkier P, Henriksen D . Statin use before and after the KDIGO Lipids in chronic kidney disease guideline: A population-based interrupted time series analysis. Basic Clin Pharmacol Toxicol. 2022; 131(5):306-310. PMC: 9795967. DOI: 10.1111/bcpt.13768. View

18.

Ward N, Watts G, Eckel R . Statin Toxicity. Circ Res. 2019; 124(2):328-350. DOI: 10.1161/CIRCRESAHA.118.312782. View

19.

Verdoodt A, Honore P, Jacobs R, De Waele E, Van Gorp V, De Regt J . Do Statins Induce or Protect from Acute Kidney Injury and Chronic Kidney Disease: An Update Review in 2018. J Transl Int Med. 2018; 6(1):21-25. PMC: 5874483. DOI: 10.2478/jtim-2018-0005. View

20.

Wanner C, Krane V, Marz W, Olschewski M, Mann J, Ruf G . Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005; 353(3):238-48. DOI: 10.1056/NEJMoa043545. View